Cargando…

Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes

BACKGROUND: Today, with the progress of medical sciences, increasing the cure probability and survival time is an important goal of cancer treatment. This study compared long-term disease-free survival (DFS) of non-metastatic breast cancer patients based on different molecular subtypes. METHODS: Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fendereski, Afsaneh, Hajizadeh, Ebrahim, Haghighat, Shahpar, Rasekhi, Aliakbar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254545/
https://www.ncbi.nlm.nih.gov/pubmed/35787692
http://dx.doi.org/10.1186/s12905-022-01846-3
_version_ 1784740723848904704
author Fendereski, Afsaneh
Hajizadeh, Ebrahim
Haghighat, Shahpar
Rasekhi, Aliakbar
author_facet Fendereski, Afsaneh
Hajizadeh, Ebrahim
Haghighat, Shahpar
Rasekhi, Aliakbar
author_sort Fendereski, Afsaneh
collection PubMed
description BACKGROUND: Today, with the progress of medical sciences, increasing the cure probability and survival time is an important goal of cancer treatment. This study compared long-term disease-free survival (DFS) of non-metastatic breast cancer patients based on different molecular subtypes. METHODS: This retrospective cohort study consisted of 1287 patients diagnosed with breast cancer and treated at Motamed Cancer Institute from 2000 to 2016 and followed up until 2018. Kaplan–Meier curve was fitted to data based on molecular subtypes. Then the semi-parametric mixture cure model was applied to determine the survival and cure probability of molecular subtypes by adjusting clinical and demographic factors. RESULTS: Among 1287 breast cancer patients, 200 (15.5%) cases died. The mean age of patients was 47.00 ± 10.72 years. Women with the HR+/HER2-subtype had the best 5-year survival rate (84.2%), whereas other subtypes had a lower rate as follows: HR+/HER2+ (77.3%), triple-negative (76.5%), and HR−/HER2+ (62.3%). Kaplan–Meier curve calculated a cure rate of about 60% and patients who survived more than 150 months were intuitively considered cured. After adjustment for clinical and demographic variables, the cure probability of HR−/Her2+ patients was substantially lower than HR+/HER2– patients (OR = 0.22), though there were no significant variations in short-term DFS based on molecular subtypes (HR = 0.91). CONCLUSIONS: Our results confirm that the most prevalent breast cancer was HR+/HER2− tumor type which had the best prognosis. It is also concluded that HR−/HER2+ patients had the worst outcomes, with the highest rates of recurrence and metastasis and the lowest overall and disease-free survival rates.
format Online
Article
Text
id pubmed-9254545
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92545452022-07-06 Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes Fendereski, Afsaneh Hajizadeh, Ebrahim Haghighat, Shahpar Rasekhi, Aliakbar BMC Womens Health Research BACKGROUND: Today, with the progress of medical sciences, increasing the cure probability and survival time is an important goal of cancer treatment. This study compared long-term disease-free survival (DFS) of non-metastatic breast cancer patients based on different molecular subtypes. METHODS: This retrospective cohort study consisted of 1287 patients diagnosed with breast cancer and treated at Motamed Cancer Institute from 2000 to 2016 and followed up until 2018. Kaplan–Meier curve was fitted to data based on molecular subtypes. Then the semi-parametric mixture cure model was applied to determine the survival and cure probability of molecular subtypes by adjusting clinical and demographic factors. RESULTS: Among 1287 breast cancer patients, 200 (15.5%) cases died. The mean age of patients was 47.00 ± 10.72 years. Women with the HR+/HER2-subtype had the best 5-year survival rate (84.2%), whereas other subtypes had a lower rate as follows: HR+/HER2+ (77.3%), triple-negative (76.5%), and HR−/HER2+ (62.3%). Kaplan–Meier curve calculated a cure rate of about 60% and patients who survived more than 150 months were intuitively considered cured. After adjustment for clinical and demographic variables, the cure probability of HR−/Her2+ patients was substantially lower than HR+/HER2– patients (OR = 0.22), though there were no significant variations in short-term DFS based on molecular subtypes (HR = 0.91). CONCLUSIONS: Our results confirm that the most prevalent breast cancer was HR+/HER2− tumor type which had the best prognosis. It is also concluded that HR−/HER2+ patients had the worst outcomes, with the highest rates of recurrence and metastasis and the lowest overall and disease-free survival rates. BioMed Central 2022-07-04 /pmc/articles/PMC9254545/ /pubmed/35787692 http://dx.doi.org/10.1186/s12905-022-01846-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Fendereski, Afsaneh
Hajizadeh, Ebrahim
Haghighat, Shahpar
Rasekhi, Aliakbar
Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes
title Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes
title_full Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes
title_fullStr Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes
title_full_unstemmed Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes
title_short Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes
title_sort long-term outcomes of non-metastatic breast cancer patients by molecular subtypes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254545/
https://www.ncbi.nlm.nih.gov/pubmed/35787692
http://dx.doi.org/10.1186/s12905-022-01846-3
work_keys_str_mv AT fendereskiafsaneh longtermoutcomesofnonmetastaticbreastcancerpatientsbymolecularsubtypes
AT hajizadehebrahim longtermoutcomesofnonmetastaticbreastcancerpatientsbymolecularsubtypes
AT haghighatshahpar longtermoutcomesofnonmetastaticbreastcancerpatientsbymolecularsubtypes
AT rasekhialiakbar longtermoutcomesofnonmetastaticbreastcancerpatientsbymolecularsubtypes